Myelodysplastic Syndromes Clinical Trial
Official title:
Revlimid®, and Metronomic Melphalan in the Management of Higher Risk Myelodysplastic Syndromes (MDS) and CMML: A Phase 2 Study"
Angiogenesis increases in higher risk MDS patients and those with proliferative CMML. Angiogenesis is associated with increased risk of leukemic transformation and poorer prognoses. Low dose chemotherapy may have anti-angiogenic properties by targetting the genetically stable endothelial cells. Lenalidomide has been recently shown to be highly effective as monotherapy in low/low-intermediate risk MDS, particularly in the subgroup harboring a 5q- deletion. Lenalidomide has not been well studied in higher risk MDS although there are some reports of lenalidomide's efficacy in RAEB-T and AML. One potential mode of action of lenalidomide is inhibition of angiogenesis. The investigators hypothesize that by combining lenalidomide with low dose melphalan in higher risk MDS the investigators will more effectively block angiogenesis and achieve responses or hematologic improvement in MDS.
STUDY OBJECTIVES:
Primary:
1. Determine the overall response rates of low dose melphalan used in combination with
lenalidomide in higher risk MDS
Secondary:
1. Determine the frequency of hematologic improvement of low dose melphalan used in
combination with lenalidomide in higher risk MDS·
2. Determine the safety and tolerability of low dose melphalan used in combination with
lenalidomide in higher risk MDS·
3. Determine the effects of low dose melphalan used in combination with lenalidomide on
biomarkers of angiogenesis in higher risk MDS·
4. Determine the frequency of cytogenetic remissions of low dose melphalan used in
combination with lenalidomide in higher risk MDS
STUDY DESIGN:
This study is a single center, open-label, non-randomized Phase II study. Patients with
higher risk MDS are included. This patient population will be defined by either high
intermediate or high risk IPSS scores or proliferative CMML with symptomatic cytopenias or
hypersplenism (IPSS score does not apply). If cytogenetics are unavailable, patients with
transfusion dependent RAEB-1 will be eligible.
This is an open label, single center non-randomized Phase II study of melphalan 2 mg po and
lenalidomide, 10 mg po daily on days 1 - 21 of a 28 day cycle in adult patients with higher
risk MDS. Patients may continue to receive drug for a maximum of 12 months or until one of
the following occur: death; disease progression (for definition, see appendix D);
intercurrent illness that prevents further administration of treatment; unacceptable adverse
event(s); patient decides to withdraw from the study; or if general or specific changes in
the patient's condition make the patient unsuitable for further treatment, or if after 4
cycles the patient is not deriving clinical benefit from the treatment in the judgment of
the investigator. After 12 months, responding patients may continue on oral lenalidomide
alone daily (at the dose tolerated by the patient) for 21 days of a 28 day cycle until
disease progression, toxicity or death.
Response to treatment and disease progression will be assessed by collecting and evaluating
bone marrow aspirates within 10 days of the first dose of cycles 3 and 5 and every three
cycles thereafter (every 12 weeks) until confirmation of a complete response. Once confirmed
1 month later, patients will not undergo bone marrow assessments until there is evidence of
progression.
Blood tests will include weekly CBC with differential and platelet count, electrolytes, BUN
and creatinine for the first 8 weeks, then every 2 weeks until on stable doses, then every 4
weeks thereafter or as clinically indicated. Liver profile will be measured monthly. Bone
marrow biopsies/aspirates will be centrally reviewed during or at the end of the study.
Approximately 30 days after receiving the last dose of study drug, patients will be
reassessed for toxicity, patient status and relapse/progression if applicable. Thereafter,
patients will be re-assessed every 3 months until death or loss to follow-up.
Biomarkers of angiogenesis will be measured at the following frequencies: CECs and CEPs at
baseline, monthly x 3 then q 3 monthly x 2 then at time of progression or coming off
study.Marrow and peripheral blood soluble VEGF and VEGFR-1 and 2 will be measured by ELISA
at the same frequency as the bone marrows.Cytogenetics will be performed at baseline, at 3
months and at completion of the study.
STUDY DURATION: 12 months for lenalidomide + melphalan; option to remain on lenalidomide
alone if ongoing response at 12 months TOTAL SAMPLE SIZE: 20
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Terminated |
NCT04313881 -
Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)
|
Phase 3 | |
Recruiting |
NCT05088356 -
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
|
Phase 1 | |
Recruiting |
NCT04003220 -
Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
|
||
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Active, not recruiting |
NCT03755414 -
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
|
Phase 1 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Terminated |
NCT04866056 -
Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.
|
Phase 1/Phase 2 | |
Recruiting |
NCT04701229 -
Haploinsufficiency of the RBM22 and SLU7 Genes in Del(5q) Myelodysplastic Syndromes
|
||
Suspended |
NCT04485065 -
Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS
|
Phase 1 | |
Recruiting |
NCT04174547 -
An European Platform for Translational Research in Myelodysplastic Syndromes
|
||
Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
Completed |
NCT02508870 -
A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes
|
Phase 1 | |
Completed |
NCT04543305 -
A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies
|
Phase 1 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Recruiting |
NCT05365035 -
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
|
Phase 2 | |
Recruiting |
NCT06008405 -
Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy
|
Phase 1 | |
Not yet recruiting |
NCT05969821 -
Clonal Hematopoiesis of Immunological Significance
|
||
Withdrawn |
NCT05170828 -
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
|
Phase 1 |